BioMarin Pharmaceutical (BMRN) Earnings Date & Reports

BioMarin reported total revenues of $766 million for the first quarter ended March 31, 2026, up 3% from $745 million in Q1 2025, slightly beating consensus estimates near $752 million. Growth stemmed from enzyme therapies ($514 million, +6%) and Voxzogo ($220 million, +3%), offset by declines in Roctavian following its voluntary U.S. market withdrawal.

GAAP diluted EPS fell 43% to $0.54 from $0.95, while non-GAAP diluted EPS declined 33% to $0.76 from $1.13, missing expectations of $0.94. The miss was driven by a $31 million charge for an unsuccessful Naglazyme (NAG) manufacturing process (reducing EPS by ~$0.12) and ~$0.07 from pre-close Amicus costs and interest. GAAP operating margin contracted to 16.9% from 30.0%, and non-GAAP to 24.3% from 35.7%, reflecting higher SG&A (selling, general, and administrative) expenses (+25%) and R&D (+13%).

Guidance for full-year 2026 was significantly raised post-acquisition: total revenues to $3.825-$3.925 billion (from prior $3.325-$3.425 billion), enzyme therapies to $2.725-$2.775 billion, Voxzogo unchanged at $975 million-$1.025 billion. Non-GAAP diluted EPS narrowed slightly to $4.85-$5.05 due to dilution, with over two-thirds weighted to H2. Operating cash flow hit $221 million, up 27% YoY.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Shares of BioMarin dipped about 0.8% in after-hours trading following the Q1 release, with a muted market response. Investors appeared to weigh the EPS shortfall and one-time charges against robust revenue beats, product momentum, and substantially raised full-year guidance incorporating Amicus contributions. Sentiment remains positive on the expanded portfolio and pipeline, though near-term dilution concerns tempered enthusiasm.

Forward Outlook and Key Factors to Monitor

BioMarin's raised 2026 guidance underscores the Amicus acquisition's impact, projecting 20% revenue growth driven by Galafold and Pombliti + Opfolda alongside core franchises. Enzyme therapies and Voxzogo are expected to sustain momentum, with over 55% of revenues in H2.

Pipeline catalysts loom large: Q2 topline data from BMN 401 Phase 3 for ENPP1 deficiency (potential 2027 launch) and Voxzogo Phase 3 for hypochondroplasia. Ongoing trials include BMN 333 Phase 2/3 for achondroplasia and BMN 351 Phase 1/2. Regulatory milestones feature Voxzogo sNDA for full approval (acceptance by Q3) and Palynziq adolescent label expansions.

Investors should track integration of Amicus assets, manufacturing resolutions like Naglazyme, and cash flow (~$2 billion cash position) amid $3.7 billion debt financing. Margin recovery, patient additions for Voxzogo/Palynziq, and competitive dynamics in rare diseases will shape trajectory. Upcoming Q2 results, expected in early August, will provide early read on combined operations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations